Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Blocking adhesion molecules with natalizumab in multiple sclerosis].

B Schreiner1, B C Kieseier, H-P Hartung

  • 1Neurologische Klinik und Poliklinik der Julius-Maximilians-Universität Würzburg.

Der Nervenarzt
|April 7, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[The Freiburg concept of the "Neurological Emergency Receiving Team (NERT)" : Concept for structuring of time-critical courses of action for patients with a predominant disability problem with an interdisciplinary and interprofessional emergency team in the nontraumatological resuscitation room].

Medizinische Klinik, Intensivmedizin und Notfallmedizin·2026
Same author

Exercise facilitates post-stroke recovery through mitigation of neuronal hyperexcitability via interleukin-10 signaling.

Nature communications·2025
Same author

Autoreactive T cells target peripheral nerves in Guillain-Barré syndrome.

Nature·2024
Same author

Factors associated with treatment escalation among MS specialists and general neurologists: Results from an International cojoint study.

Multiple sclerosis and related disorders·2022
Same author

Correcting gut dysbiosis can ameliorate inflammation and promote remyelination in multiple sclerosis - Commentary.

Multiple sclerosis (Houndmills, Basingstoke, England)·2021
Same author

Shorter infusion time of ocrelizumab: Results from the randomized, double-blind ENSEMBLE PLUS substudy in patients with relapsing-remitting multiple sclerosis.

Multiple sclerosis and related disorders·2020

Natalizumab, a treatment for multiple sclerosis (MS), was withdrawn due to safety concerns including progressive multifocal leukoencephalopathy. Further studies are investigating patient risks.

Area of Science:

  • Immunology
  • Neuroscience
  • Pharmacology

Context:

  • Natalizumab is a monoclonal antibody targeting alpha(4)-integrins, crucial for lymphocyte trafficking in autoimmune diseases.
  • It was investigated for multiple sclerosis (MS), inflammatory bowel diseases, and rheumatoid arthritis.
  • Phase III trials (AFFIRM, SENTINEL) assessed natalizumab's efficacy in relapsing-remitting MS.

Purpose:

  • To evaluate the efficacy and safety of natalizumab in treating multiple sclerosis.
  • To update on the clinical trial results and market status of natalizumab.
  • To investigate the risks associated with natalizumab therapy, particularly in combination with interferon beta-1a.

Summary:

  • Natalizumab showed initial promise for MS treatment, leading to FDA authorization based on interim analyses.

Related Experiment Videos

  • However, serious adverse events, including progressive multifocal leukoencephalopathy (PML), led to its market withdrawal in 2005.
  • Ongoing research aims to understand the risks, especially for patients in the Sentinel Study.

    • Impact:

    • The withdrawal of natalizumab highlighted the critical need for rigorous safety monitoring in MS therapeutics.
    • This event underscored the complex risk-benefit balance in treating autoimmune neurological conditions.
    • Further research is essential to determine safe treatment protocols and patient selection for immunomodulatory therapies.